Piper Sandler analyst Christopher Raymond downgraded Deciphera to Neutral from Overweight with a price target of $25.60, up from $23, after the company entered a definitive merger agreement under which ONO Pharmaceutical will acquire all outstanding shares of Deciphera common stock for $25.60 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.